Abstract 174P
Background
Application of computer and artificial intelligence (AI) has made revolutionary progress in medical fields. Computer-assisted diagnosis (CAD) on pathology is successful in diagnosis, classification, staging and predicting prognosis of cancer.
Methods
In this work, we used the technique of convolutional neural networks (CNN) for training of morphological images of gastric cancer, which is a promising application of artificial intelligence technique for medical image analysis, especially for cancer pathology.
Results
We introduced successful works of AI-aided gastric cancer analysis for over 300 cases. AI-assisted pathology technique could help the pathologist in detecting and locating the abnormal area in images and to diagnose and classify benign or malignant tissues. Therefore, AI exactly improves the diagnostic status of gastric cancer, such as in interpretation of medical images and classification between benign and cancerous tissues. The complete workflow of AI diagnosis for gastric cancer is under construction. AI is more useful in releasing pathologists from repeated work, and improving efficiency.
Conclusions
In conclusions, there are still notable technical obstacles before this approach can be used to improve conventional clinical practice. Higher performance needs corrected marking images by experienced pathologist and require ‘training’ algorithms on tremendous data. We stressed the importance of proper algorithms for improving confidence of analytic results that is close to human experts. Additionally, we indicated the gaps in current research and principal resolutions for advancing the field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors without further recourse to the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract